Rafferty Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.04M Sell
181,676
-16,587
-8% -$396K 0.02% 460
2025
Q4
$5.3M Buy
198,263
+3,232
+2% +$77.2K 0.02% 420
2025
Q3
$4.16M Buy
195,031
+69,294
+55% +$1.64M 0.01% 467
2025
Q2
$2.71M Sell
125,737
-74,552
-37% -$1.39M 0.01% 536
2025
Q1
$3.33M Buy
200,289
+50,055
+33% +$909K 0.01% 453
2024
Q4
$2.76M Sell
150,234
-135,507
-47% -$2.19M 0.01% 551
2024
Q3
$4.39M Sell
285,741
-19,338
-6% -$323K 0.02% 448
2024
Q2
$4.96M Sell
305,079
-86,146
-22% -$1.39M 0.02% 417
2024
Q1
$7.23M Sell
391,225
-36,705
-9% -$909K 0.03% 374
2023
Q4
$13.4M Buy
427,930
+91,317
+27% +$2.18M 0.06% 211
2023
Q3
$7.02M Buy
336,613
+584
+0.2% +$15.9K 0.04% 322
2023
Q2
$8.05M Buy
336,029
+3,668
+1% +$81.5K 0.05% 271
2023
Q1
$6.26M Sell
332,361
-224,320
-40% -$4.27M 0.04% 332
2022
Q4
$8.86M Buy
556,681
+158,005
+40% +$2.47M 0.07% 217
2022
Q3
$6.52M Buy
398,676
+175,222
+78% +$2.84M 0.07% 248
2022
Q2
$3.15M Sell
223,454
-7,229
-3% -$135K 0.03% 379
2022
Q1
$5.59M Sell
230,683
-6,215
-3% -$150K 0.03% 360
2021
Q4
$5.53M Buy
236,898
+43,230
+22% +$869K 0.03% 352
2021
Q3
$3.22M Buy
193,668
+98,537
+104% +$1.9M 0.02% 437
2021
Q2
$2.32M Sell
95,131
-28,091
-23% -$634K 0.01% 647
2021
Q1
$3.18M Buy
123,222
+105,036
+578% +$4.62M 0.02% 453
2020
Q4
$972K Sell
18,186
-35,995
-66% -$1.79M 0.01% 503
2020
Q3
$2.23M Buy
54,181
+33,346
+160% +$1.44M 0.03% 379
2020
Q2
$1.01M Buy
20,835
+10,427
+100% +$501K 0.01% 538
2020
Q1
$440K Sell
10,408
-78,071
-88% -$3.22M 0.02% 361
2019
Q4
$3.79M Sell
88,479
-35,204
-28% -$1.53M 0.06% 180
2019
Q3
$4.45M Sell
123,683
-77,572
-39% -$2.35M 0.07% 165
2019
Q2
$5.38M Buy
201,255
+8,735
+5% +$223K 0.09% 146
2019
Q1
$5.17M Buy
+192,520
New +$4.5M 0.08% 133

Other funds holding ACAD